The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GEHC | -14.43% | N/A | N/A | +24% |
| S&P | +18.54% | +92.9% | +14.04% | +74% |
GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.
Join us as we dissect GE Healthcare Technologies and reveal whether it's a smart investment choice or just another stock to avoid.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $5.14B | 5.8% |
| Gross Profit | $1.99B | 0.3% |
| Gross Margin | 38.73% | -2.1% |
| Market Cap | $34.29B | -20.0% |
| Market Cap / Employee | $0.65M | 0.0% |
| Employees | 53K | 3.9% |
| Net Income | $464.00M | -5.3% |
| EBITDA | $846.00M | -0.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.03B | 12.9% |
| Accounts Receivable | $4.44B | 8.3% |
| Inventory | 2.3K | 8.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.61B | -10.5% |
| Short Term Debt | $2.14B | 90.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.34% | 1.3% |
| Return On Invested Capital | 11.85% | 0.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $483.00M | -25.5% |
| Operating Free Cash Flow | $593.00M | -19.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 18.01 | 16.97 | 15.16 | 15.53 | -39.59% |
| Price to Book | 4.29 | 4.37 | 3.69 | 3.53 | -31.52% |
| Price to Sales | 1.82 | 1.87 | 1.70 | 1.70 | -23.03% |
| Price to Tangible Book Value | -6.00 | -6.40 | -6.25 | -6.96 | -3.32% |
| Price to Free Cash Flow TTM | 24.00 | 28.13 | 22.53 | 25.65 | -2.28% |
| Enterprise Value to EBITDA | 40.78 | 54.64 | 53.12 | 48.78 | -17.70% |
| Free Cash Flow Yield | 4.2% | 3.6% | 4.4% | 3.9% | 2.34% |
| Return on Equity | 25.6% | 26.3% | 25.6% | 24.2% | 11.60% |
| Total Debt | $9.38B | $9.18B | $10.72B | $10.74B | 0.10% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
